SE9804001D0 - New process - Google Patents

New process

Info

Publication number
SE9804001D0
SE9804001D0 SE9804001A SE9804001A SE9804001D0 SE 9804001 D0 SE9804001 D0 SE 9804001D0 SE 9804001 A SE9804001 A SE 9804001A SE 9804001 A SE9804001 A SE 9804001A SE 9804001 D0 SE9804001 D0 SE 9804001D0
Authority
SE
Sweden
Prior art keywords
solvent
substance
treatment
water
formulations
Prior art date
Application number
SE9804001A
Other languages
English (en)
Inventor
Mikael Bisrat
Mustafa Demirbueker
Saeed Moshashaee
Haakan Nyqvist
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20413378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9804001(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9804001A priority Critical patent/SE9804001D0/sv
Publication of SE9804001D0 publication Critical patent/SE9804001D0/sv
Priority to PCT/SE1999/002153 priority patent/WO2000030613A1/en
Priority to DE69920946T priority patent/DE69920946T3/de
Priority to JP2000583497A priority patent/JP4616993B2/ja
Priority to PT99963730T priority patent/PT1133284E/pt
Priority to DK99963730T priority patent/DK1133284T4/da
Priority to AU20103/00A priority patent/AU767767B2/en
Priority to AT99963730T priority patent/ATE278391T1/de
Priority to CA002348084A priority patent/CA2348084C/en
Priority to US09/486,689 priority patent/US6461642B1/en
Priority to EP99963730A priority patent/EP1133284B2/en
Priority to ES99963730T priority patent/ES2228149T5/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
SE9804001A 1998-11-23 1998-11-23 New process SE9804001D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE9804001A SE9804001D0 (sv) 1998-11-23 1998-11-23 New process
ES99963730T ES2228149T5 (es) 1998-11-23 1999-11-22 Un procedimiento para la preparacion de particulas cristalinas.
EP99963730A EP1133284B2 (en) 1998-11-23 1999-11-22 A process for the preparation of crystalline particles
JP2000583497A JP4616993B2 (ja) 1998-11-23 1999-11-22 新しい製造方法
DE69920946T DE69920946T3 (de) 1998-11-23 1999-11-22 Verfahren zur herstellung kristalliner partikel
PCT/SE1999/002153 WO2000030613A1 (en) 1998-11-23 1999-11-22 New process
PT99963730T PT1133284E (pt) 1998-11-23 1999-11-22 Um processo para a preparacao de particulas cristalinas
DK99963730T DK1133284T4 (da) 1998-11-23 1999-11-22 Fremgangsmåde til fremstilling af krystallinske partikler
AU20103/00A AU767767B2 (en) 1998-11-23 1999-11-22 New process
AT99963730T ATE278391T1 (de) 1998-11-23 1999-11-22 Verfahren zur herstellung kristalliner partikel
CA002348084A CA2348084C (en) 1998-11-23 1999-11-22 Crystallisation using supercritical or subcritical fluids
US09/486,689 US6461642B1 (en) 1998-11-23 1999-11-22 Crystallization using supercritical or subcritical fluids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9804001A SE9804001D0 (sv) 1998-11-23 1998-11-23 New process

Publications (1)

Publication Number Publication Date
SE9804001D0 true SE9804001D0 (sv) 1998-11-23

Family

ID=20413378

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9804001A SE9804001D0 (sv) 1998-11-23 1998-11-23 New process

Country Status (12)

Country Link
US (1) US6461642B1 (sv)
EP (1) EP1133284B2 (sv)
JP (1) JP4616993B2 (sv)
AT (1) ATE278391T1 (sv)
AU (1) AU767767B2 (sv)
CA (1) CA2348084C (sv)
DE (1) DE69920946T3 (sv)
DK (1) DK1133284T4 (sv)
ES (1) ES2228149T5 (sv)
PT (1) PT1133284E (sv)
SE (1) SE9804001D0 (sv)
WO (1) WO2000030613A1 (sv)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH694686A5 (it) 2000-03-04 2005-06-15 Eco2 Sa Prodotto di micronizzazione di sostanze farmaceutiche.
GB0016040D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
ES2170008B1 (es) * 2000-08-25 2003-05-01 Soc Es Carburos Metalicos Sa Procedimiento para la precipitacion de particulas solidas finamente divididas.
FR2815540B1 (fr) * 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB0102075D0 (en) * 2001-01-26 2001-03-14 Astrazeneca Ab Process
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
IL160570A0 (en) 2001-09-26 2004-07-25 Baxter Int Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
JP2005511521A (ja) * 2001-10-10 2005-04-28 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 加圧ガス状流体による粉末処理
FR2830760B1 (fr) * 2001-10-12 2004-06-04 Pf Medicament Procede de preparation d'un compose d'interaction de substances actives avec un support poreux par fluide supercritique
CN1726010A (zh) * 2002-12-19 2006-01-25 巴克斯特国际公司 使用超临界流体制备组合药物制剂的方法
EP1624862B1 (en) 2003-05-08 2014-12-31 Nektar Therapeutics Particulate materials
JP2007501194A (ja) * 2003-08-05 2007-01-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ステロイドとβ模倣薬を含む吸入用薬剤
EP1701775B2 (en) * 2003-11-19 2012-06-13 NATEX Prozesstechnologie GesmbH A method and process for controlling the temperature, pressure and density profiles in dense fluid processes and associated apparatus
EP1904219A4 (en) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc METHOD FOR FORMING PARTICLES
EP1782839A1 (en) 2005-11-03 2007-05-09 Genetic S.p.A. Sterilization process of Glucocorticosteroid by supercritical CO2
EP2049086A2 (en) * 2006-08-09 2009-04-22 Glaxo Group Limited Process for manufacturing lactose
EP2425819A1 (en) 2007-02-11 2012-03-07 MAP Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
WO2009047935A1 (ja) * 2007-10-12 2009-04-16 Ono Pharmaceutical Co., Ltd. 微粒子
JP5307382B2 (ja) * 2007-11-14 2013-10-02 日機装株式会社 微粒子化方法
CN101918123B (zh) 2007-12-07 2013-12-18 X喷雾微粒公司 生产微粒的方法与装置
DE102008053618A1 (de) * 2008-10-29 2010-07-01 Karlsruher Institut für Technologie Verfahren zur Ausfällung von Salzen
ES2342140B1 (es) 2008-12-30 2011-05-17 Consejo Superior Investigacion Procedimiento para la obtencion de micro- o nanoparticulas solidas
US20100298602A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Systems and methods for microfluidic crystallization
US20100294986A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Supercritical fluid facilitated particle formation in microfluidic systems
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
CN102327186A (zh) * 2011-09-30 2012-01-25 四川大学 一种采用超临界co2流体技术制备水溶性药物缓释微粒的方法
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3744329A1 (de) * 1987-12-28 1989-07-06 Schwarz Pharma Gmbh Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US6063910A (en) † 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5639441A (en) * 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
US5301664A (en) * 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
WO1994008599A1 (en) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9313650D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9703673D0 (en) 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
AU741783B2 (en) 1997-03-20 2001-12-06 Merck Sharp & Dohme Corp. Preparation of powder agglomerates

Also Published As

Publication number Publication date
ATE278391T1 (de) 2004-10-15
PT1133284E (pt) 2005-01-31
ES2228149T5 (es) 2008-12-16
AU767767B2 (en) 2003-11-20
EP1133284A1 (en) 2001-09-19
JP2002530318A (ja) 2002-09-17
CA2348084C (en) 2009-01-06
DK1133284T4 (da) 2008-11-10
EP1133284B2 (en) 2008-08-06
EP1133284B1 (en) 2004-10-06
DK1133284T3 (da) 2005-02-28
DE69920946D1 (de) 2004-11-11
WO2000030613A1 (en) 2000-06-02
AU2010300A (en) 2000-06-13
DE69920946T3 (de) 2009-02-26
JP4616993B2 (ja) 2011-01-19
CA2348084A1 (en) 2000-06-02
DE69920946T2 (de) 2005-08-25
US6461642B1 (en) 2002-10-08
ES2228149T3 (es) 2005-04-01

Similar Documents

Publication Publication Date Title
SE9804001D0 (sv) New process
EE200100275A (et) Kristalsesse olekusse konverteeritud amorfse ja/või metastabiilse kristalse piirkonnaga osakeste valmistamismeetod
ATE168556T1 (de) Stabile budesonid-lösungen, verfahren zu deren herstellung sowie verwendung dieser lösungen als klistierzubereitungen und pharmazeutische schäume
MXPA03004883A (es) Metodo para la estabilizacion de biomoleculas (por ejemplo, insulina) en formulaciones liquidas.
IS8870A (is) Lyfjablanda sem felur í sér andrógen
EA199800531A1 (ru) Водные суспензии сложных эфиров жирной кислоты 9-гидроксирисперидона
ATE147976T1 (de) Protein nanomatrizen und verfahren zur herstellung
IL146659A0 (en) Porous drug matrices and method of manufacture thereof
ES2130622T3 (es) Sistema para la administracion transdermica de farmacos.
ES2165936T3 (es) Procedimiento para la fabricacion de una formulacion terapeutica liposomal seca y solida, dispersable en agua, de administracion oral.
DE69735634D1 (de) Substituierte cyclopentanderivate die als neuramidase-inhibitoren nuetzlich sind
ATE234089T1 (de) Zubereitungen enthaltend sclareol und sclareolide zur behandlung mikrobieller infektionen
ATE269057T1 (de) Arzneizubereitungen und deren herstellungsverfahren
ES2155746B1 (es) Procedimiento y aparato para la produccion de carbon activo.
BR0316123A (pt) Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico
RU2000130144A (ru) Способ кислородной пассивации и очистки стальных труб
NO20005725L (no) Biologisk aktiv sammensetning
ATE12649T1 (de) Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.
HUP0401943A2 (hu) A 2alfa, 3alfa, 17alfa-trihidroxi-5alfa-androsztán-6-on alkalmazása a növényi fejlődés szabályozására a növényt érő stressz hatásának csökkentése által
RU2003115986A (ru) Способ лечения сенсоневральной тугоухости
RU2002104671A (ru) Способ лечения гнойных ран
RU2001125131A (ru) Способ лечения кератопатии
JPS5220991A (en) Activity regeneration method of active carbon for aqueous treatment an d its apparatus
TH19245A (th) วิธีป้องกันการสลายของโปรตีนซี